Bionano Genomics, a San Diego-based biotech firm, has announced the appointment of Alex Hastie as its new chief scientific officer. In this role, Hastie will be responsible for leading the development of the company's genetic analysis technologies, including its proprietary optical mapping platform.
Hastie brings over 20 years of experience in the field of genetic analysis, with a strong focus on its applications in disease diagnosis. Prior to joining Bionano Genomics, he held various senior roles at companies such as Thermo Fisher Scientific and Illumina, where he played a key part in the development of next-generation sequencing technologies.
The appointment of Hastie is a significant coup for Bionano Genomics, which is at the forefront of the development of optical mapping technologies for the analysis of large genomes. The company's technologies have significant potential in the diagnosis and treatment of complex diseases, including cancer and neurodegenerative disorders.
Bionano Genomics is a global leader in the development of optical mapping technologies, with a strong presence in the UK. The company's technologies have been used in various research studies, including those focused on the diagnosis and treatment of cancer.
While the appointment of Hastie is a significant development for Bionano Genomics, it is unclear at this time what impact it will have on the wider UK biotech sector. However, it is likely that Hastie's expertise will be in high demand, and it is possible that he may be involved in various collaborations and partnerships in the UK and elsewhere.